Kai Li

11PUBLICATIONS
15CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsOncology and carcinogenesis not elsewhere classifiedGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 29, 2024
Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial.

Cuicui Zhang, Tianqing Chu, Qiming Wang

|Jun 23, 2023
Immune-independent acquired resistance to PD-L1 antibody initiated by PD-L1 upregulation via PI3K/AKT signaling can be reversed by anlotinib.

Yuan Gao, Yingfang Feng, Shaochuan Liu

|Jul 24, 2021
Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer.

Cuicui Zhang, Jing Wang, Xinyue Wang

|Jul 17, 2021
Occurrence of hypertension during third-line anlotinib is associated with progression-free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial.

Jianhua Shi, Guimin Chen, Haitao Wang

|Mar 12, 2021
Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial.

Tianqing Chu, Jun Lu, Minghong Bi

|Sep 18, 2020
Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling.

Tingting Qin, Zhujun Liu, Jing Wang

Pageof 2

Frequent Collaborators

4 joint publications

Baohui Han

1 joint publications

Richeng Jiang

1 joint publications

Dingzhi Huang

1 joint publications

Cory J Xian